X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Gossamer intends to use the net proceeds to fund the ongoing development and commercialization of GB002 (seralutinib), a tyrosine kinase inhibitor targeting PDGFRα/β, CSF1R, and c-KIT, for the treatment of pulmonary arterial hypertension (PAH).
Lead Product(s): Seralutinib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: GB002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: New Enterprise Associates
Deal Size: $212.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement July 20, 2023
Details:
The efficacy results generated with GB002 (seralutinib) in the context of a favorable safety and tolerability profile highlight compelling potential differentiation for seralutinib as an anti-proliferative, anti-inflammatory, and anti-fibrotic therapeutic candidate.
Lead Product(s): Seralutinib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: GB002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2022
Details:
Gossamer intends to use the net proceeds from the proposed financing to fund research and development of its other product candidates and development programs and for working capital and general corporate purposes.
Lead Product(s): Seralutinib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: GB002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: EcoR1 Capital
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement July 13, 2022
Details:
Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor. The primary objective for this trial is to determine the effect of GB002 on improving pulmonary hemodynamics in subjects with WHO Group 1 PAH who are Functional Class II and III.
Lead Product(s): Seralutinib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GB002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
